Literature DB >> 22564844

Effect of coadministration of vancomycin and BMP-2 on cocultured Staphylococcus aureus and W-20-17 mouse bone marrow stromal cells in vitro.

A H Nguyen1, S Kim, W J Maloney, J C Wenke, Y Yang.   

Abstract

In this study, we aimed to establish an in vitro bacterium/bone cell coculture model system and to use this model for dose dependence studies of dual administration of antibiotics and growth factors in vitro. We examined the effect of single or dual administration of the antibiotic vancomycin (VAN) at 0 to 16 μg/ml and bone morphogenetic protein-2 (BMP-2) at 0 or 100 ng/ml on both methicillin-sensitive Staphylococcus aureus and mouse bone marrow stromal cells (W-20-17) under both mono- and coculture conditions. Cell metabolic activity, Live/Dead staining, double-stranded DNA (dsDNA) amounts, and alkaline phosphatase activity were measured to assess cell viability, proliferation, and differentiation. An interleukin-6 (IL-6) enzyme-linked immunosorbent assay (ELISA) kit was used to test the bone cell inflammation response in the presence of bacteria. Our results suggest that, when delivered together in coculture, VAN and BMP-2 maintain their primary functions as an antibiotic and a growth factor, respectively. Most interestingly, this dual-delivery type of approach has shown itself to be effective at lower concentrations of VAN than those required for an approach relying strictly on the antibiotic. It may be that BMP-2 enhances cell proliferation and differentiation before the cells become infected. In coculture, a dosage of VAN higher than that used for treatment in monoculture may be necessary to effectively inhibit growth of Staphylococcus aureus. This could mean that the coculture environment may be limiting the efficacy of VAN, possibly by way of bacterial invasion of the bone cells. This report of a coculture study demonstrates a potential beneficial effect of the coadministration of antibiotics and growth factors compared to treatment with antibiotic alone.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22564844      PMCID: PMC3393469          DOI: 10.1128/AAC.00114-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  50 in total

Review 1.  Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?

Authors:  J Ciampolini; K G Harding
Journal:  Postgrad Med J       Date:  2000-08       Impact factor: 2.401

Review 2.  Advances in our understanding of the bone and joint pathology caused by Staphylococcus aureus infection.

Authors:  S P Nair; R J Williams; B Henderson
Journal:  Rheumatology (Oxford)       Date:  2000-08       Impact factor: 7.580

Review 3.  Prevention of infections associated with combat-related extremity injuries.

Authors:  Clinton K Murray; William T Obremskey; Joseph R Hsu; Romney C Andersen; Jason H Calhoun; Jon C Clasper; Timothy J Whitman; Thomas K Curry; Mark E Fleming; Joseph C Wenke; James R Ficke
Journal:  J Trauma       Date:  2011-08

Review 4.  Dual delivery of an antibiotic and a growth factor addresses both the microbiological and biological challenges of contaminated bone fractures.

Authors:  Joseph C Wenke; Scott A Guelcher
Journal:  Expert Opin Drug Deliv       Date:  2011-10-22       Impact factor: 6.648

5.  Intracellular Staphylococcus aureus induces apoptosis in mouse osteoblasts.

Authors:  K A Tucker; S S Reilly; C S Leslie; M C Hudson
Journal:  FEMS Microbiol Lett       Date:  2000-05-15       Impact factor: 2.742

6.  In vivo internalization of Staphylococcus aureus by embryonic chick osteoblasts.

Authors:  S S Reilly; M C Hudson; J F Kellam; W K Ramp
Journal:  Bone       Date:  2000-01       Impact factor: 4.398

7.  Staphylococcus aureus infection of mouse or human osteoblasts induces high levels of interleukin-6 and interleukin-12 production.

Authors:  K L Bost; W K Ramp; N C Nicholson; J L Bento; I Marriott; M C Hudson
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

8.  Silver dressings augment the ability of negative pressure wound therapy to reduce bacteria in a contaminated open fracture model.

Authors:  Daniel J Stinner; Scott M Waterman; Brendan D Masini; Joseph C Wenke
Journal:  J Trauma       Date:  2011-07

9.  In vitro release of vancomycin and tobramycin from impregnated human and bovine bone grafts.

Authors:  H Winkler; O Janata; C Berger; W Wein; A Georgopoulos
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

10.  Involvement of mitogen-activated protein kinase pathways in Staphylococcus aureus invasion of normal osteoblasts.

Authors:  J K Ellington; A Elhofy; K L Bost; M C Hudson
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

View more
  5 in total

1.  Tunable staged release of therapeutics from layer-by-layer coatings with clay interlayer barrier.

Authors:  Jouha Min; Richard D Braatz; Paula T Hammond
Journal:  Biomaterials       Date:  2013-12-31       Impact factor: 12.479

2.  Novel osteoinductive photo-cross-linkable chitosan-lactide-fibrinogen hydrogels enhance bone regeneration in critical size segmental bone defects.

Authors:  Sungwoo Kim; Katherine Bedigrew; Teja Guda; William J Maloney; Sangwon Park; Joseph C Wenke; Yunzhi Peter Yang
Journal:  Acta Biomater       Date:  2014-08-28       Impact factor: 8.947

3.  Tailored sequential drug release from bilayered calcium sulfate composites.

Authors:  Bryan R Orellana; David A Puleo
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2014-07-09       Impact factor: 7.328

4.  In Situ Gelling Hydrogel with Anti-Bacterial Activity and Bone Healing Property for Treatment of Osteomyelitis.

Authors:  Sun Woo Jung; Se Heang Oh; In Soo Lee; June-Ho Byun; Jin Ho Lee
Journal:  Tissue Eng Regen Med       Date:  2019-08-22       Impact factor: 4.169

5.  Bone morphogenetic proteins - 7 and - 2 in the treatment of delayed osseous union secondary to bacterial osteitis in a rat model.

Authors:  Lars Helbig; Georg W Omlor; Adriana Ivanova; Thorsten Guehring; Robert Sonntag; J Philippe Kretzer; Susann Minkwitz; Britt Wildemann; Gerhard Schmidmaier
Journal:  BMC Musculoskelet Disord       Date:  2018-07-27       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.